The fight against cancer, while making significant strides in recent decades, continues to be marred by the harsh reality of chemotherapy’s side effects. For patients undergoing treatment, the toxic impact on healthy cells often becomes as debilitating as the disease itself, leading to immense suffering and, at times, treatment discontinuation. It is this profound challenge that Bhubaneswar-based biotech firm Exsure is determined to address, and their recent Rs 3 crore seed funding round, led by Unicorn India Ventures, marks a crucial validation of their innovative approach to making cancer treatment less punishing.
This capital infusion arrives at a pivotal moment for Exsure, propelling its patented drug-delivery platform further into preclinical development and signaling a growing investor appetite for deep-tech, life sciences solutions emerging from India. The investment isn’t just about the money; it represents a vote of confidence in a scientific premise that could fundamentally alter the patient experience in oncology, unlocking pathways to more targeted and tolerable therapies. As the Indian biotech ecosystem matures, attracting serious capital for long-horizon projects like drug development, Exsure’s journey highlights a promising shift towards addressing global health challenges with indigenous innovation.
About Exsure: Revolutionizing Targeted Cancer Therapy
Founded in 2021 by the visionary duo of Swastika Paul and Abhishek Dutta, Exsure emerged from a shared doctoral research background and a deeply personal understanding of chemotherapy’s collateral damage. Both founders had witnessed firsthand the severe toll conventional treatments take on cancer patients, sparking a commitment to devise a gentler, yet more effective, alternative. Exsure, presently incubated at KIIT-TBI, is a biotech company focused on developing a patented drug-delivery platform that aims to make chemotherapy less toxic by precisely targeting cancer cells and cancer stem cells.
At the heart of Exsure’s innovation lies its proprietary exosome-based platform. Exosomes are tiny, naturally occurring vesicles that cells release to transport materials, acting as intercellular messengers. Exsure has ingeniously engineered these exosomes to serve as targeted delivery vehicles for chemotherapy drugs, ensuring that the therapeutic agents are concentrated exactly where they are needed: within the tumor, including the elusive cancer stem cells often responsible for recurrence. This precision minimizes exposure to healthy tissues, mitigating the debilitating side effects associated with standard chemotherapy. The company’s scientific rigor is underscored by peer-reviewed research, with its platform described in detail in a 2024 paper in Frontiers in Bioengineering and Biotechnology.
While the primary drug development program is still in preclinical stages, having completed part of a preclinical study and initiated a non-clinical study with a contract research organization in India, Exsure has strategically built a complementary revenue stream. The company actively sells a range of research products, including Exosure (an exosome isolation reagent), Leucosure, PlantExosure, and the Dr Berries line, to laboratories and research institutions. Furthermore, it offers specialized outsourcing services such as cancer stem cell isolation and targeted exosome preparation to other researchers. This dual-pronged strategy provides essential income and customer engagement, offering a crucial lifeline and demonstrating commercial viability as the capital-intensive, multi-year journey of drug development progresses. The institutional backing from BIRAC, the government’s biotechnology funding body, alongside its incubator, has been instrumental in enabling this early-stage, deep-science work, particularly for a biotech venture located outside the traditional research hubs.
The Seed Capital Infusion: Fueling Preclinical Advancement
In January 2025, Exsure successfully closed its seed funding round, raising Rs 3 crore. This crucial capital was led by Unicorn India Ventures, a firm renowned for its early-stage investments in disruptive technology and deep-tech companies across various sectors, including healthcare and life sciences. While specific valuation details were not publicly disclosed, the investment itself speaks volumes about the perceived potential of Exsure’s scientific breakthrough.
Unicorn India Ventures’ investment thesis often centers on backing companies with strong intellectual property, a clear problem-solving approach, and the potential for significant market disruption. Their decision to lead Exsure’s seed round underscores their confidence in the foundational science behind the exosome delivery platform, its patented nature, and the long-term vision of its founders. For a venture firm, the dual revenue model, balancing the immediate commercialization of research products with the long-term drug development pipeline, likely presented an attractive risk mitigation strategy in the typically high-risk biotech sector. This strategic investment also highlights Unicorn India Ventures’ commitment to fostering innovation that can address critical societal needs, aligning well with Exsure’s mission to alleviate patient suffering. The firm’s involvement provides not just capital, but also strategic guidance and access to a broader network, invaluable assets for a nascent biotech enterprise.
Strategic Deployment: Accelerating R&D and Market Reach
The Rs 3 crore secured in this seed round is earmarked for precise and critical operational advancements. A significant portion of the funds will be channeled towards the completion of Exsure’s ongoing non-clinical study. This phase is paramount, as it provides essential data on the safety and efficacy of their drug candidate before any potential human trials can be considered. The successful completion of this study will be a major milestone, de-risking the technology and paving the way for future regulatory approvals and clinical development.
Beyond the core drug development, the capital will also be strategically deployed to expand the sales and market reach of Exsure’s existing research products. This includes an ambitious plan to grow sales beyond India, tapping into international laboratories and research institutions that require advanced reagents and specialized services. This expansion will not only bolster the company’s revenue streams but also establish its reputation within the global scientific community, creating a virtuous cycle of revenue generation supporting further research and development. This balanced approach to capital deployment ensures that Exsure maintains financial stability while diligently progressing its long-term, high-impact drug development goals. The funds will likely also support the hiring of specialized scientific talent and strengthening their intellectual property portfolio as they advance.
Tackling a Global Health Crisis: The Market Opportunity
The global cancer therapeutics market is a colossal and ever-expanding landscape, driven by rising incidence rates, an aging population, and continuous innovation. Valued in the hundreds of billions of dollars, it presents an enormous opportunity for solutions that can offer superior patient outcomes. Within this market, the segment for targeted therapies and novel drug delivery systems is experiencing particularly rapid growth, as the medical community increasingly seeks alternatives to broad-spectrum treatments.
Exsure’s value proposition directly addresses a critical unmet need: reducing the severe toxicity of chemotherapy while simultaneously combating drug resistance by targeting cancer stem cells. Current conventional chemotherapy, while effective, indiscriminately attacks rapidly dividing cells, leading to systemic side effects like hair loss, nausea, fatigue, and immune suppression. Moreover, the persistence of cancer stem cells after treatment is a significant factor in disease relapse, a problem Exsure’s exosome platform is engineered to tackle.
The competitive landscape includes established pharmaceutical giants developing new chemotherapy agents, targeted therapies (like monoclonal antibodies and small molecule inhibitors), and immunotherapies. However, Exsure’s unique positioning lies in its exosome-based delivery system, which offers unparalleled precision. While other companies are exploring various drug delivery mechanisms, Exsure’s patented technology, rooted in strong scientific publications, provides a distinct advantage in terms of targeted delivery to both cancer cells and, critically, the often-resistant cancer stem cells. This dual targeting mechanism potentially offers a more comprehensive and durable therapeutic effect, differentiating it significantly from current offerings. The ability to concentrate the drug at the tumor site not only enhances efficacy but also dramatically improves the patient’s quality of life during treatment, a monumental step forward in cancer care.
What’s Next for Exsure: Milestones on the Horizon
With the seed capital firmly in place, Exsure is now poised to hit several critical milestones over the coming months and years. The immediate focus is the successful and timely completion of the non-clinical study for its lead drug candidate. This data will be instrumental in informing the next steps, including potential regulatory filings and the arduous, yet essential, journey towards human clinical trials. While clinical trials are still several years away, given the rigorous and protracted nature of drug development, each preclinical success brings the company closer to its ultimate goal.
In parallel with its drug development efforts, Exsure plans to aggressively expand the commercial footprint of its research products. This includes scaling up manufacturing, enhancing distribution networks, and forging new partnerships to reach a broader base of academic and industrial research laboratories globally. Success in this area will not only provide a robust revenue stream but also build the company’s brand and scientific credibility within the international biotech community.
Looking further ahead, Exsure’s trajectory will undoubtedly involve subsequent funding rounds, likely a Series A, once significant preclinical milestones are achieved or substantial commercial traction is demonstrated with its research products. The founders, Swastika Paul and Abhishek Dutta, are driven by a long-term vision to fundamentally transform cancer treatment, making it less agonizing for patients worldwide. Their commitment to scientific excellence and patient-centric innovation positions Exsure as a promising player in the global fight against cancer, one small, yet incredibly significant, exosome at a time. This seed round is not merely an investment in a company; it is an investment in a future where the battle against cancer is fought with precision, compassion, and renewed hope.
